Phenytoin Antibody (Mouse Monoclonal)

<strong>Mouse Phenytoin Antibody (Monoclonal)</strong>. 6 different clones are available._x000D_ <table width="452">_x000D_ <tbody>_x000D_ <tr>_x000D_ <td><strong>Catalog #</strong></td>_x000D_ <td>A2010005-1E5_x000D_ _x000D_ A2010005-4D8_x000D_ _x000D_ A2010005-8H9_x000D_ _x000D_ A2010005-2C6_x000D_ _x000D_ A2010005-5H7_x000D_ _x000D_ A2010005-9F3_x000D_ _x000D_ A2010005-SET</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td><strong>Size</strong></td>_x000D_ <td>0.25 mg</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td><strong>Other Names</strong></td>_x000D_ <td>Mab to Phenytoin, antibody to Phenytoin</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td><strong>Host</strong></td>_x000D_ <td>Mouse</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td><strong>Concentration</strong></td>_x000D_ <td>1.0 mg/mL</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td><strong>Purity</strong></td>_x000D_ <td>&gt;90% (protein A column)</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td><strong>Storage</strong></td>_x000D_ <td>-20°C. Avoid repeated freeze/thaw cycles.</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td><strong>Supplied as</strong></td>_x000D_ <td>Liquid solution</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td><strong>Buffer</strong></td>_x000D_ <td>1X Phosphate Buffer Saline, pH 7.4 + 0.05% sodium azide.</td>_x000D_ </tr>_x000D_ <tr>_x000D_ <td><strong>Keywords</strong></td>_x000D_ <td>Phenytoin, mouse monoclonal antibody</td>_x000D_ </tr>_x000D_ </tbody>_x000D_ </table>_x000D_ &nbsp;_x000D_ _x000D_ <strong>References</strong>_x000D_ <ul>_x000D_ <li>Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action. <span class="labs-docsum-authors full-authors">Keppel Hesselink JM, Kopsky DJ.</span> <span class="labs-docsum-journal-citation full-journal-citation">J Neurol. 2017 Aug;264(8):1617-1621. </span></li>_x000D_ <li>Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.<span class="labs-docsum-authors full-authors"> DeToledo JC, Ramsay RE.</span> <span class="labs-docsum-journal-citation full-journal-citation">Drug Saf. 2000 Jun;22(6):459-66. </span></li>_x000D_ <li>Application of in vivo metabolomics to preclinical/toxicological studies: case study on phenytoin-induced systemic toxicity.<span class="labs-docsum-authors full-authors"> Kamp H, Fabian E, Groeters S, Herold M, Krennrich G, Looser R, Mattes W, Mellert W, Prokoudine A, Ruiz-Noppinger P, Strauss V, Walk T, Wiemer J, van Ravenzwaay B.</span> <span class="labs-docsum-journal-citation full-journal-citation">Bioanalysis. 2012 Sep;4(18):2291-301. </span></li>_x000D_ <li>Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.<span class="labs-docsum-authors full-authors"> Johnson GJ, Kilpatrick CJ, Bury RW, Fullinfaw RO, Moulds RF.</span> <span class="labs-docsum-journal-citation full-journal-citation">Br J Clin Pharmacol. 1989 Jun;27(6):843-9.</span></li>_x000D_ <li>Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration.<span class="labs-docsum-authors full-authors"> Boucher BA, Bombassaro AM, Rasmussen SN, Watridge CB, Achari R, Turlapaty P.</span> <span class="labs-docsum-journal-citation full-journal-citation">J Pharm Sci. 1989 Nov;78(11):929-32. </span></li>_x000D_ <li>Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit.<span class="labs-docsum-authors full-authors"> Muchohi SN, Kokwaro GO, Maitho TE, Munenge RW, Watkins WM, Edwards G.</span> <span class="labs-docsum-journal-citation full-journal-citation">Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun;27(2):83-9. </span></li>_x000D_ <li>Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats.<span class="labs-docsum-authors full-authors"> Burstein AH, Cox DS, Mistry B, Eddington ND.</span> <span class="labs-docsum-journal-citation full-journal-citation">Epilepsy Res. 1999 Apr;34(2-3):129-33.</span></li>_x000D_ <li>Phenytoin as an effective treatment for polymorphic ventricular tachycardia due to QT prolongation in a patient with multiple drug intolerances.<span class="labs-docsum-authors full-authors"> Yager N, Wang K, Keshwani N, Torosoff M.</span> <span class="labs-docsum-journal-citation full-journal-citation">B<a href="https://pubmed.ncbi.nlm.nih.gov/26071440/">MJ Case Rep.</a> 2015 Jun 12;2015:bcr2015209521. </span></li>_x000D_ </ul>